Delving into the Latest Updates on Vortex Biotechnology Corp with Synapse

Overview

In this issue of Blood, Avila Avila et al1 report that T-cell acute lymphoblastic leukemia (T-ALL) cells overcome anti-CD3 monoclonal antibody (mAb)-directed therapy by inducing tumor necrosis factor receptor (TNFR) signaling, leading to activation of the NF-κB pathway (see figure).Combining teplizumab, an inhibitor of CD3, with etanercept, a decoy receptor for tumor necrosis factor-α (TNF-α), inhibited human T-ALL patient-derived xenograft (PDX) growth in mouse models, suggesting the importance of this pathway.Remarkably, coadministration of birinapant, which mimics the downstream regulator secondary mitochondrial-derived activator of caspases (SMAC), redirected prosurvival TNFR signaling into a parallel, apoptotic program and led to growth suppression and even complete cure in one human T-ALL model.This combination therapy demonstrates how an unwanted cell-signaling outcome can be rechanneled to improve overall treatment efficacy.Anti-CD3 combination therapy can be a new bridge to allogeneic stem cell transplant.

100 Deals associated with Vortex Biotechnology Corp

Login to view more data

100 Translational Medicine associated with Vortex Biotechnology Corp

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data